PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein that is only expressed on the surface of myeloma cells. This initiates antibody-dependent cellular cytotoxicity activity that kills myeloma cells and leaves healthy cells intact.

“My experience working with XVIVO can be summed up in one word: Confidence. Confidence in the depth of scientific knowledge they contributed, this knowledge only enhanced the end product, was evident as a core competency from our initial discussions even before engaging them for the production, and inspired our team because they were collaborating with a partner who is as dedicated to the science of the story as they are.”
VP, Director of Production, JUICE Pharma Advertising